Thalassemia bone disease: A 19-year longitudinal analysis

Journal of Bone and Mineral Research

Volumn 29, Issue 11, 2014, Pages 2468-2473

  Wong, Phillip ^a,b,c   Fuller, Peter J ^a,b,c   Gillespie, Matthew T ^a,c   Kartsogiannis, Vicky ^a   Kerr, Peter G ^b,c   Doery, James C G ^b,c   Paul, Eldho ^c   Bowden, Donald K ^b   Strauss, Boyd J ^c   Milat, Frances ^a,b,c  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b SOUTHERN HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

bone density; bone disease; osteoporosis; thalassemia

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DEFERASIROX; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; PHOSPHATE; IRON CHELATING AGENT;

ADULT; ANEMIA; ARTICLE; BETA THALASSEMIA; BODY MASS; BONE DENSITY; BONE DISEASE; CALCIUM BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FERRITIN BLOOD LEVEL; FOLLOW UP; FRACTURE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN H DISEASE; HUMAN; HYPOGONADISM; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PHOSPHATE BLOOD LEVEL; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; THALASSEMIA; THALASSEMIA INTERMEDIA; BLOOD TRANSFUSION; CHILD; CLINICAL TRIAL; COMPLICATION; IRON OVERLOAD; METABOLISM; PATHOLOGY;

ADULT; BLOOD TRANSFUSION; BONE DENSITY; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LONGITUDINAL STUDIES; MALE; OSTEOPOROSIS; SEX FACTORS; THALASSEMIA;

EID: 84916221057     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2266     Document Type: Article

References (37)

1. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al., Survival and complications in thalassemia. Ann NY Acad Sci. 2005; 1054: 40-7.
2. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR., Complications of β-thalassemia major in North America. Blood. 2004; 104 (1): 34-9.
3. Vogiatzi MG, Macklin EA, Fung EB, et al., Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009; 24 (3): 543-57.
4. Haidar R, Musallam KM, Taher AT., Bone disease and skeletal complications in patients with β thalassemia major. Bone. 2011; 48 (3): 425-32.
5. Fung EB, Harmatz PR, Milet M, et al., Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone. 2008; 43 (1): 162-8.
6. Mahachoklertwattana P, Pootrakul P, Chuansumrit A, et al., Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. J Bone Miner Metab. 2006; 24 (2): 146-52.
7. Pootrakul P, Hungsprenges S, Fucharoen S, et al., Relation between erythropoiesis and bone metabolism in thalassemia. N Eng J Med. 1981; 304 (24): 1470-3.
8. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, et al., Bone histomorphometry in children and adolescents with β-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab. 2003; 88 (8): 3966-72.
9. Milat F, Wong P, Fuller PJ, et al., A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. J Bone Miner Res. 2012; 27 (1): 219-22.
10. Olivieri NF, Koren G, Harris J, et al., Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol. 1992; 14 (1): 48-56.
11. Morabito N, Russo GT, Gaudio A, et al., The "lively" cytokines network in β-thalassemia major-related osteoporosis. Bone. 2007; 40 (6): 1588-94.
12. Scacchi M, Danesi L, Cattaneo A, et al., Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites. Clin Endocrinol. 2008; 69 (2): 202-7.
13. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R., Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol. 2003; 58 (3): 273-9.
14. Wong P, Fuller PJ, Gillespie MT, et al., Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int. 2013; 24 (7): 1965-71.
15. Anapliotou MLG, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P., The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol. 1995; 42 (3): 279-87.
16. Wong P, Fuller PJ, Gillespie MT, et al., The effect of gonadal status on body composition and bone mineral density in transfusion-dependent thalassemia. Osteoporos Int. 2013; 25 (2): 597-604.
17. Filosa A, Di Maio S, Vocca S, Saviano A, Esposito G, Pagano L., Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatr. 1997; 86 (4): 342-6.
18. Molyvda-Athanasopoulou E, Sioundas A, Karatzas N, Aggellaki M, Pazaitou K, Vainas I., Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int. 1999; 64 (6): 481-4.
19. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher. Guidelines for the clinical management of thalassaemia. Nicosia, Cyprus: Thalassaemia International Federation; 2008. p. 25.
20. Pasricha S-R, Frazer DM, Bowden DK, Anderson GJ., Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood. 2013; 122 (1): 124-33.
21. Haidar R, Mhaidli H, Musallam KM, Taher AT., The spine in β-thalassemia syndromes. Spine. 2012; 37 (4): 334-9.
22. Hartkamp MJ, Babyn PS, Olivieri F., Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients. Pediatr Radiol. 1993; 23 (7): 525-8.
23. Ladis V, Raptou P, Rigatou E, et al., Study of bone density by pQCT analysis in healthy adults and patients with B-Thalassemia major and intermedia. Pediatr Endocrinol Rev. 2008; 6(Suppl 1): 127-31.
24. Mylona M, Leotsinides M, Alexandrides T, Zoumbos N, Dimopoulos PA., Comparison of DXA, QCT and trabecular structure in β-thalassaemia. Eur J Haematol. 2005; 74 (5): 430-7.
25. Even-Or E, Becker-Cohen R, Miskin H., Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol. 2010; 85 (2): 132-4.
26. Toumba M, Sergis A, Kanaris C, Skordis N., Endocrine complications in patients with thalassaemia major. Pediatr Endocrinol Rev. 2007; 5 (2): 642-8.
27. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N., Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int. 2001; 12 (7): 570-5.
28. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E., Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997; 82 (8): 2386-90.
29. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al., Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89 (10): 1187-93.
30. Yamasaki K, Hagiwara H., Excess iron inhibits osteoblast metabolism. Toxicol Lett. 2009; 191 (2-3): 211-5.
31. De Vernejoul MC, Pointillart A, Cywiner Golenzer C., Effects of iron overload on bone remodeling in pigs. Am J Pathol. 1984; 116 (3): 377-84.
32. Kim BJ, Ahn SH, Bae SJ, et al., Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: a 3-year retrospective longitudinal study. J Bone Miner Res. 2012; 27 (11): 2279-90.
33. Messer JG, Cooney PT, Kipp DE., Iron chelator deferoxamine alters iron-regulatory genes and proteins and suppresses osteoblast phenotype in fetal rat calvaria cells. Bone. 2010; 46 (5): 1408-15.
34. Naderi M, Sadeghi-Bojd S, Valeshabad AK, et al., A prospective study of tubular dysfunction in pediatric patients with beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol. 2013; 30 (8): 748-54.
35. Favus MJ., Hypercalciuric bone disease. In:, Evan AP, Williams JC, Lingeman JE, McAteer JA, editors. Renal stone disease 2: 2nd International Urolithiasis Research Symposium. AIP Conference Proceedings, vol. 1049. College Park, MD: American Institute of Physics; pp. 17-24. 2008.
36. Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG., FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009; 94 (7): 2332-7.
37. Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D., Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998; 28 (3): 695-9.